ADRX-0706 is a Nectin-4 ADC being evaluated in the Phase 1b portion of an ongoing Phase 1a/b clinical trial (NCT06036121) for the treatment of select advanced solid tumors, including cervical cancer.

New data presented at AACR supports adding pembrolizumab before and after surgery in patients with newly diagnosed locally ...

So, right now, the standard of care for advanced cervical cancer, if you are a candidate for immunotherapy, is actually to receive four drugs at the same time, two chemotherapies, a platinum-based ...

The new data from the phase 3 innovaTV 301 study will be filed with the FDA in the hope of converting the accelerated approval for Tivdak (tisotumab vedotin) for women with advanced cervical ...

The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology. The fourth leading cause of ...

In locally advanced head and neck cancers, the tumor has spread to nearby tissues or lymph nodes but has not yet metastasized to distant organs. Standard-of-care therapy for these patients ...

The vertebral canal in the neck can narrow over time due to age-related changes, leading to compression of the spinal cord and nerves. Other causes include spine trauma, rheumatoid arthritis and bone ...

Genmab has received approval from the Japan's Ministry of Health, Labour and Welfare for Tivdak (tisotumab vedotin) to treat advanced or recurrent cervical cancer that progressed on or following ...